within Pharmacolibrary.Drugs.R_RespiratorySystem.R03C_AdrenergicsForSystemicUse.R03CC02_Salbutamol;

model Salbutamol_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.75e-06,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.074,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.105,
    k12 = 2.233333333333334e-05,
    k21 = 2.233333333333334e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Salbutamol_1</td></tr><tr><td>ATC code:</td><td>R03CC02_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>74</td><td>L</td></tr>
    <tr><td>clearance:</td><td>13.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Salbutamol (also known as albuterol) is a short-acting β2 adrenergic receptor agonist used for the rapid relief and prevention of bronchospasm in conditions such as asthma and COPD. It is globally approved and widely utilized in acute symptomatic management as well as prevention of exercise-induced bronchospasm.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Vet, NJ, et al., &amp; de Hoog, M (2020). Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. <i>Clinical pharmacokinetics</i> 59(2) 257–264. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00811-y\">10.1007/s40262-019-00811-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31432470/\">https://pubmed.ncbi.nlm.nih.gov/31432470</a></p></li><li><p>Marques, L, &amp; Vale, N (2024). Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients. <i>Pharmaceutics</i> 17(1) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics17010039\">10.3390/pharmaceutics17010039</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39861686/\">https://pubmed.ncbi.nlm.nih.gov/39861686</a></p></li><li><p>Antoniu, S (2014). Bedoradrine for treating asthma and chronic obstructive pulmonary disease. <i>Expert opinion on investigational drugs</i> 23(8) 1149–1156. DOI:<a href=\"https://doi.org/10.1517/13543784.2014.928284\">10.1517/13543784.2014.928284</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24938936/\">https://pubmed.ncbi.nlm.nih.gov/24938936</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03CC02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Salbutamol_1;
